Page 9 - Rob Winder News Today : Breaking News, Live Updates & Top Stories | Vimarsana

th Annual Global Healthcare Conference PureTech Health plc (LSE: PRTC, Nasdaq: PRTC) ("PureTech" or the "Company"), a clinical-stage biotherapeutics company dedicated to discovering, developing and commercializing highly differentiated medicines for devastating diseases, today announced that Bharatt Chowrira, Ph.D., J.D., President and Chief of Business and Strategy, George Farmer, Ph.D., Chief Financial Officer, and Michael Chen, Ph.D., Head of Innovation, will participate in a fireside chat at the SVB Leerink 10 th Annual Global Healthcare Conference on Friday, February 26 th at 10:0...

  PureTech Adds Bharatt Chowrira, PureTech's President and Chief of Business and Strategy, to Board of Directors     PureTech Health plc (LSE: PRTC, Nasdaq: PRTC) ("PureTech" or the "Company"), a clinical-stage biotherapeutics company dedicated to discovering, developing and commercializing highly differentiated medicines for devastating diseases, today announces the appointment of Bharatt Chowrira, Ph.D., J.D., to its Board of Directors as an executive director. Dr. Chowrira has served as PureTech's President and Chief of Business and Strategy since March 2017 and...

PureTech Founded Entity Vedanta Biosciences Announces $25 Million Investment from Pfizer Inc. Michael Vincent, M.D., Ph.D., Chief Scientific Officer, Inflammation & Immunology Research Unit at Pfizer,   to join Vedanta's Scientific Advisory Board   PureTech Health plc (LSE: PRTC, NASDAQ: PRTC) ("PureTech" or the "Company"), a clinical-stage biotherapeutics company dedicated to discovering, developing and commercializing highly differentiated medicines for devastating diseases , is pleased to note that its Founded Entity, Vedanta Bi...

An MGH pilot study evaluating scalp skin disruption using Follica’s proprietary Hair Follicle Neogenesis stimulation product was published in International Journal of Women’s Dermatology, demonstrating the treatment promoted hair growth in female pattern hair loss. The study endpoints included photographs, patient-reported improvement and physician-documented Sinclair score. The pilot study, led by Maryanne M. Senna, M.D., an assistant professor of dermatology at Harvard Medical School, enrolled 11 women with mild to moderate FPHL who had been on stable existing treatments for six or more...

  Study will further evaluate safety and tolerability of LYT-100 and explore clinical efficacy endpoints in patients with breast-cancer related, upper limb secondary lymphedema   Previously announced results from multiple ascending dose and food effect study in healthy volunteers demonstrated favorable tolerability and pharmacokinetic proof-of-concept for LYT-100   A separate Phase 2 study evaluating LYT-100 in Long COVID respiratory complications and related sequelae was recently initiated     PureTech Health plc (LSE: PR...